Table 1.

Association between baseline hematology values and PFS or OS in the unadjusted and adjusted analysis in dataset L

Unadjusted analysis	PFS				OS
		HR	98.3% CI	P	HR	98.3% CI	P
Neutrophil count	N = 2012	1.05	1.03–1.07	<0.001	1.07	1.05–1.09	<0.001
Platelet count	N = 2047	1.00	1.00–1.00	0.236	1.00	1.00–1.00	0.877
Hemoglobin	N = 2052	1.07	1.00–1.15	0.016	1.08	1.01–1.17	0.011
Adjusted analysis	PFS				OS
	N = 2002	HR	98.3% CI	P	HR	98.3% CI	P
Baseline neutrophils	2002 (100.0)	1.02	1.00–1.05	0.011	1.05	1.02–1.07	<0.001
Baseline platelets	2002 (100.0)	1.00	1.00–1.00	0.040	1.00	1.00–1.00	0.838
Baseline hemoglobin	2002 (100.0)	1.01	0.94–1.10	0.670	1.02	0.93–1.11	0.588
Sex
Male	1206 (60.2)	1			1		0.036
Female	796 (39.8)	0.88	0.76–1.00	0.018	0.88	0.76–1.02
Age group
< 55 years	850 (42.5)	1			1		<0.001
≥ 55 years	1152 (57.5)	1.17	1.04–1.32	0.002	1.45	1.27–1.66
WHO performance status
0	1024 (51.1)	1			1		<0.001
>0	978 (48.9)	1.11	0.99–1.26	0.032	1.24	1.09–1.42
MGMT promoter
Unmethylated	802 (40.1)	1		<0.001			<0.001
Methylated	807 (40.3)	0.54	0.46–0.62		0.44	0.37–0.52
Unknown	393 (19.6)	0.80	0.67–0.95		0.81	0.68–0.98
Extent of surgery
Partial resection or biopsy	1120 (55.9)	1		<0.001	1		<0.001
Gross total resection	882 (44.1)	0.78	0.69–0.88		0.74	0.65–0.84
MMSE
< 27	449 (22.4)	1		<0.001	1		<0.001
≥ 27	1475 (73.7)	0.78	0.68–0.91		0.76	0.65–0.88
Unknown	78 (3.9)	0.99	0.58–1.69		1.14	0.65–2.01
Steroid use at baseline
No	1116 (55.7)	1		0.172	1		0.033
Yes	886 (44.3)	1.08	0.94–1.24		1.14	0.98–1.32

MGMT, O⁶-methylguanine DNA methyltransferase; MMSE, Mini-Mental State Examination; N, number of patients; OS, overall survival; PFS, progression-free survival; WHO, World Health Organization